VTE

The Challenges at the Intersection of VTE and Obesity: Defining the Issues
The Challenges at the Intersection of VTE and Obesity: Defining the Issues
CME, CNE, CE
Rachel P. Rosovsky, MD, MPH; Stephan Moll, MD; and Bishoy Ragheb, PharmD, BCACP, CDE, CACP, CTTS
Release Date: February 14, 2024
Expiration Date: February 14, 2025

This activity, the first in a two-part series, focuses on the effects of obesity on VTE and anticoagulation therapy. Follow along with the faculty as they clarify the relationship between obesity and VTE and outline strategies for tailoring anticoagulation therapy based on body mass index (BMI) and other relevant factors. A case study is included to help demonstrate the challenges of – and solutions to – anticoagulation therapy in this patient population.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc. administered by Janssen Scientific Affairs, LLC.
Begin, Earn CreditView Only, No Credit
 
Anticoagulation in Obese Patients: Applied Clinical Practices in the Non-specialist Setting
Anticoagulation in Obese Patients: Applied Clinical Practices in the Non-specialist Setting
CME, CNE, CE
Rachel P. Rosovsky, MD, MPH; Stephan Moll, MD; and Bishoy Ragheb, PharmD, BCACP, CDE, CACP, CTTS
Release Date: February 14, 2024
Expiration Date: February 14, 2025

This activity, the second in a two-part series, explores anticoagulation treatment strategies in special patient groups, including patients with heavy menses, renal issues, or a history of bariatric surgery. This activity is designed to equip its participants with strategies for ensuring optimal anticoagulation in a variety of situations in patients both with and without obesity.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc. administered by Janssen Scientific Affairs, LLC.
Begin, Earn CreditView Only, No Credit
 
VTE Pathophysiology and DOAC Pharmacokinetics in Obesity
VTE Pathophysiology and DOAC Pharmacokinetics in Obesity
CME, CPE
Daniel M. Witt, PharmD, FCCP, BCPS
Release Date: March 31, 2022
Expiration Date: March 31, 2023

Join Dr. Witt as he explains how to optimize DOAC pharmacokinetics in patients with obesity. Topics include hemostasis, the impact of obesity on clot formation, and the effects of obesity on DOAC absorption, distribution, metabolism, and excretion.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.
CE ExpiredView Only, No Credit
 
Direct Oral Anticoagulants in Patients with Venous Thromboembolism and Obesity
Direct Oral Anticoagulants in Patients with Venous Thromboembolism and Obesity
CME, CPE
Rachel P. Rosovsky, MD, MPH and Stephan Moll, MD
Release Date: January 30, 2023
Expiration Date: January 30, 2024

In this activity, two experts discuss direct oral anticoagulants (DOACs) in patients with VTE and obesity and review updated guidelines. They will discuss safety and appropriate dosing strategies for patients with a certain BMI, as well as the use of prophylaxis. The program will conclude with a discussion on the use of DOACs in patients after bariatric surgery.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC.
CE ExpiredView Only, No Credit
 
Improving Care Disparities for Black Americans in Mississippi with Venous Thromboembolism: The Role of Care Transitions in Critical Access Hospitals
Improving Care Disparities for Black Americans in Mississippi with Venous Thromboembolism: The Role of Care Transitions in Critical Access Hospitals
CME, CPE, CNE
Charles V. Pollack, Jr., MD, FACEP, FAAEM, FAHA, FACC, FESC, FCPP; DeGail J. Hadley, DO; Cynthia Harrington, DNP, APRN, FNP-BC, PMHNP-BC, NEd, MT(ASCP); Elizabeth Hood, PharmD
Release Date: June 02, 2021
Expiration Date: June 02, 2022

This activity is designed to educate clinicians on how to reduce care disparities and health outcomes for Black Americans in rural Mississippi with a venous thromboembolism (VTE) diagnosis, as they make the transition from a Critical Access Hospital (CAH) back into their own communities on oral anticoagulants.

This activity was previously presented as a live webinar with Q&A during May 2021. Please note: If you participated in the live webinar, you are ineligible to receive an additional 1.5 contact hours of credit and may not re-submit for credit previously awarded.

Provided by MediCom Worldwide, Inc.
This activity is supported by an educational grant from the Bristol-Myers Squibb and Pfizer Alliance.

This program would not have been possible without the support and dedication of resources from the Mississippi State Medical Association, Mississippi Hospital Association, National Blood Clot Alliance, and the Mississippi Business Group on Health.
CE ExpiredView Only, No Credit
 

© 2024 MediCom Worldwide, Inc. All rights reserved